DNTH dianthustx.com: Multiplikator Forward P/S
Dianthus Therapeutics develops innovative antibodies to combat inflammation through strategic biotech partnerships. The projected P/S metric allows for an assessment of market revenue expectations, and its latest value is recorded as 1893.10. Outlook depends on the safety of the DNTH103 molecule and the rate of capital burn, while geopolitical factors exert no influence on the development of the company's clinical trials.
Dianthus Therapeutics, Inc. - rincian analitis lan metrik utama (DNTH)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- statistik nilai buku emiten:
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Dianthus Therapeutics|DNTH - Rasio utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Dianthus Therapeutics|DNTH - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Dianthus Therapeutics Inc|DNTH - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Dianthus Therapeutics|Likuiditas cepet dianthustx.com
- rincian asil keuangan lan kelipatan valuasi:
DNTH - Asil keuangan resik|Bathi mangsa ngarep Dianthus Therapeutics|DNTH - Nilai perusahaan marang bathi resik|Prakiraan rega marang bathi Dianthus Pharma|DNTH - Rasio nilai perusahaan marang wutah bathi|Pangali EV/EBITDA Dianthus Therapeutics Inc|DNTH - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Dianthus Therapeutics|DNTH - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan dianthustx.com|DNTH - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Dianthus Therapeutics
- indikator volume dodolan lan pendapatan:
Analisis umum perusahaan:Dianthus Pharma DNTH
Dianthus Therapeutics (DNTH) competes in the high-risk immunotherapy segment, where success depends on clinical trial results. The forward P/S ratio compares current market capitalization with expected sales volume to determine the premium for future growth. Analyzing the projected price-to-sales ratio allows for an assessment of investor appetite for financing biotech projects. The dynamics of this coefficient reflect the balance between market optimism and fundamental development risks.
Pesaing wigati
Multiplikator Forward P/S ARGX (argenx.com)|BioNTech Group (BNTX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ABIVAX - Multiplikator Forward P/S|ADMA - Multiplikator Forward P/S|Protagonist (PTGX) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Immunovant Inc|Rasio rega marang prakiraan pendapatan Kiniksa Pharmaceuticals|Grifols Group (GRFS) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Adaptive Biotechnologies Corp (ADPT)|Rasio rega marang prakiraan pendapatan CLDX (Celldex Therapeutics)|Rasio rega marang prakiraan pendapatan Aurinia Pharma AUPH|Rega forward marang dodolan BCRX|VERA: Multiplikator forward rega marang pendapatan|PHVS - Multiplikator Forward P/S|ABCL: Multiplikator Forward P/S|TRML (Tourmaline Bio, Inc.) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Intrexon|PHAR - Prakiraan rega marang pendapatan|Multiplikator Forward P/S NKTR|Rasio rega marang prakiraan pendapatan UPB (Upstream Bio Corp)|Rasio rega marang prakiraan pendapatan Zenas Biopharma, Inc. ZBIO|Rasio kapitalisasi marang dodolan sing dikarepake immunome.com (IMNM)|Gossamer Bio Inc - Multiplikator Forward P/S|Rega forward marang dodolan KALV (KalVista Pharmaceuticals, Inc.)|SEPN: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Pieris Pharmaceuticals Inc|Multiplikator forward rega marang pendapatan SVRA|Multiplikator forward rega marang pendapatan Rigel Pharmaceuticals (RIGL)|Multiplikator Forward P/S ANAB|ATXS - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan enGene Corp ENGN|Rasio kapitalisasi marang dodolan sing dikarepake RAPT Therapeutics, Inc. (RAPT)|Aerovate - Multiplikator Forward P/S|ACRS - Multiplikator Forward P/S|KYTX (Kyverna Therapeutics) - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Tiziana Life Sciences Ltd. (TLSA)|Multiplikator forward rega marang pendapatan CABA|Ventyx Biosciences (VTYX) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S THTX|AVTX (Avalo Therapeutics, Inc) - Rega forward marang dodolan|Multiplikator Forward P/S ELDN (eledon.com)|AGEN - Multiplikator forward rega marang pendapatan|CLYM - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan ZURA|ATYR: Multiplikator Forward P/S|Adagene Corp (ADAG) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan IMA|Shattuck Labs, Inc. - Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Equillium Inc (EQ)|Multiplikator Forward P/S Connect Biopharma Holdings (CNTB)|Rasio rega marang prakiraan pendapatan Immunic, Inc. IMUX|Multiplikator Forward P/S Atara Biotherapeutics ATRA|IFRX - Rasio rega marang prakiraan pendapatan|XFOR: Rasio rega marang prakiraan pendapatan|ACET: Multiplikator Forward P/S|CELU - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan inmunebio.com|Kapitalisasi marang prakiraan pendapatan BRNS (barinthusbio.com)|Multiplikator Forward P/S KZR|Multiplikator Forward P/S SAB Biotherapeutics, Inc (SABS)|Multiplikator Forward P/S AKTX (Akari Therapeutics, Plc)|Multiplikator Forward P/S enlivex.com ENLV|QTTB: Multiplikator forward rega marang pendapatan|GOVX - Multiplikator Forward P/S|Edesa Biotech Inc (EDSA) - Rasio rega marang prakiraan pendapatan|IBIO - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan carismatx.com|XTLB: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Bolt Biotherapeutics Inc. (BOLT)|HCW Biologics - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan aptevotherapeutics.com APVO|AIM - Multiplikator forward rega marang pendapatan|Aditxt - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake GRI Bio Corporation GRI|xortx.com (XRTX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep reshapelifesciences.com (HIND)|Rasio rega marang prakiraan pendapatan Revelation Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Indaptus Therapeutics, Inc. INDP|Rasio rega marang prakiraan pendapatan BiondVax Pharmaceuticals (SCNI)|Multiplikator forward rega marang pendapatan CalciMedica CALI|Rasio rega marang prakiraan pendapatan Affimed AFMD|ALLK - Multiplikator forward rega marang pendapatan|HOOKIPA Pharma, Inc. - Multiplikator Forward P/S|Rega forward marang dodolan IGMS (igmbio.com)|ITOS (iTeos Therapeutics, Inc.) - Multiplikator forward rega marang pendapatan|Ocean Biomedical Corp (OCEA) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan TC BioPharm (Holdings) PLC|Multiplikator Forward P/S thirdharmonicbio.com
